市場調査レポート

ファーマコビジランス市場 (医薬品開発の段階、手法の種類、サービスの種類):世界の産業分析、規模、シェア、成長率、動向、予測 (2014年〜2020年)

Pharmacovigilance Market (Phases of Drug Development, Type of Methods, Type of Service) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

発行 Transparency Market Research 商品コード 328530
出版日 ページ情報 英文 151 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
ファーマコビジランス市場 (医薬品開発の段階、手法の種類、サービスの種類):世界の産業分析、規模、シェア、成長率、動向、予測 (2014年〜2020年) Pharmacovigilance Market (Phases of Drug Development, Type of Methods, Type of Service) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
出版日: 2015年03月30日 ページ情報: 英文 151 Pages
概要

製薬企業は、現在、創薬から市販後承認までのファーマコビジランス (医薬品安全性監視) プロセス関連の支出を削減するために、CRO・BPOとの長期的なパートナーシップ/サービス契約を締結しています。

当レポートでは、世界のファーマコビジランス市場について調査分析し、現状と将来市場に焦点を当てて、セグメント別分析、地域別分析、主要企業プロファイルなどについて、体系的な情報を提供しています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 世界のファーマコビジランス市場の動向

  • イントロダクション
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • ファイブフォース分析:世界のファーマコビジランス市場
  • 市場の魅力分析:世界のファーマコビジランス市場 (地域別)
  • 競合情勢

第4章 世界のファーマコビジランス市場:医薬品開発の段階別

  • 概要
  • 前臨床試験
  • 第1相
  • 第2相
  • 第3相
  • 第4相または市販後調査

第5章 世界のファーマコビジランス市場:手法の種類別

  • 概要
  • 比較分析
  • 有害事象報告
  • 自発報告
  • コホート事象監視
  • EHR検索

第6章 世界のファーマコビジランス市場:サービス提供者の種類別

  • 概要
  • 社内ファーマコビジランス
  • 外部委託契約

第7章 世界のファーマコビジランス市場:地域別

  • 概要
  • 北米
  • 欧州
  • アジア太平洋地域
  • その他

第8章 提言

第9章 企業プロファイル

  • Accenture plc
  • Bristol-Myers Squibb
  • Clinquest Group B.V.
  • Cognizant Technology Solutions
  • Covance, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc (GSK)
  • ICON plc
  • iGATE Corporation
  • iMEDGlobal Corporation
  • inVentiv Health, Inc.
  • Novartis International AG
  • PAREXEL International Corporation
  • Pfizer, Inc.
  • Pharmaceutical Product Development, LLC. (PPD)
  • PRA Health Sciences, Inc.
  • Quintiles Transnational Holdings, Inc.
  • Sanofi
  • Synowledge LLC
  • Wipro Limited

図表

目次

Intensifying regulatory expectations, tougher inspection system, and instant need for patient reporting boost the adoption rate of pharmacovigilance among pharmaceutical companies. Rise in the prevalence of acute and chronic diseases has consequently led to an increase in the incidences of drug consumption, thus leading to growth in the number of adverse drug events and drug toxicity cases. Furthermore, safety regulations, risk of high-profile safety issues, large volume of post-market events to be reviewed along with negative media coverage have bound the pharmaceutical players to take support of various outsourcing services for drug monitoring. Two major outsourcing providers preferred by pharmaceutical manufacturers for pharmacovigilance services are namely, traditional CROs (e.g. Covance, Inc., Quintiles Transnational, INC Research, etc.) and BPOs (e.g. Capgemini, Cognizant, Infosys Ltd., Tata Consultancy Services Limited, etc.). Outsourcing services do not only help in cost saving, but also support process efficiency. Pharmaceutical companies are now entering into long-term partnerships/service agreements with CROs and BPOs to reduce the pharmacovigilance process related expenditure, incurred right from drug discovery to post-marketing approvals. In addition, pharmacovigilance requires skilled resources with excellent language skills and strong knowledge pertaining to case reporting due to which pharmaceutical companies are opting for outsourced pharmacovigilance services in order to reduce the burden of clerical functions as well as capital expenditures.

This report provides a detailed analysis of the global pharmacovigilance market and assists in understanding various market regulating factors. The market overview section in this report provides analysis of the overall market trends and market dynamics such as market driving factors, restraining factors, and opportunities, which currently administrate the dynamics of the overall pharmacovigilance market. Additionally, the segment also provides and predicts the future circumstances of the market. Market monitoring tools such as Porter's five forces analysis is also included in this study to provide analysis about the competition in the pharmacovigilance market and market attractiveness in various regions across the world. Competitive analysis tools such as market share analysis and market attractive analysis have also been included in the market overview section of the report to deliver a comprehensive status of the players in the global pharmacovigilance market. The executive summary provided in this report reflects the highlights of the study scope and the overall market in a summarized form. Furthermore, it includes a market snapshot, which provides a glance at the current scenario of the global pharmacovigilance market in terms of current and future market size and growth.

The global pharmacovigilance market is segmented on the basis of clinical trial phases, type of methods, service providers, and geography. Based on clinical trial phases, the pharmacovigilance market is segmented into preclinical studies, phase I trial, phase II trial, phase III trial, and phase IV trial (post marketing surveillance). Based on the methods, this study segments the market into spontaneous reporting, targeted reporting, cohort event monitoring, Intensified ADR, and Reporting EHR mining. Based on service providers, the global pharmacovigilance market is categorized into in-house and contract outsourcing. The market size estimations for the period from 2012 to 2020 have been provided for each segment in terms of USD million. Compounded annual growth rates (CAGR %) for each segment has been provided for the period between 2014 and 2020, considering 2013 as the base year.

In terms of regional analysis, the global pharmacovigilance market has been segmented into four key geographies: North America, Europe, Asia Pacific, and Rest of World (RoW). Market revenue estimations for each of these geographies have been provided in the report for the period from 2012 to 2020 in terms of USD million, considering 2013 as the base year for calculations and 2012 as the historical year. The CAGR (%) of each market segment for the forecast period from 2014 to 2020 has also been provided along with market size estimations. This study also provides recommendations for players of the global pharmacovigilance market, which include aspects that may play a decisive role in improving the market share.

The report concludes with in-depth profiles of leading players, which include key information about the major organizations dynamically involved in the global pharmacovigilance market. The report profiles the key market players in terms of company overview, financial overview, product portfolio, business strategies, and recent developments. The key companies profiled in this study are Accenture, Plc, Clinquest Group B.V., Cognizant Technology Solutions, Covance, Inc. ICON, Plc, iMED Global Corporation, inVentiv Health, Inc., Parexel International Corporation, Pharmaceutical Product Development LLC, PRA Health Sciences, Inc., Quintiles Transnational Holdings Inc, F. Hoffmann-La Roche Ltd., Sanofi , Synowledge LLC, Wipro Limited. Market share analysis of the organizations operating in the pharmacovigilance market would help new entrants to understand key business policies and identify product portfolio of established companies.

The global pharmacovigilance market is segmented as follows:

Pharmacovigilance Market, by Phases of Drug Development

  • Preclinical Studies
  • Phase I
  • Phase II
  • Phase III
  • Phase IV or Post Marketing Surveillance

Pharmacovigilance Market, by Type of Methods

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

Pharmacovigilance Market, by Type of Service

  • In-House
  • Contract Outsourcing

Pharmacovigilance Market, by Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World (RoW)

Table of Contents

Chapter 1 Introduction

  • 1.1 Report Description
  • 1.2 Research Methodology
  • 1.3 Market Segmentation

Chapter 2 Executive Summary

Chapter 3 Global Pharmacovigilance Market Dynamics

  • 3.1 Introduction
  • 3.2 Market Drivers
    • 3.2.1 Increasing Consumption of Drugs Would Fuel Demand for Continuous Drug Event Monitoring
    • 3.2.2 Rise in the Cases of Adverse Drug Reactions and Drug Toxicity Would Boost Demand for Pharmacovigilance Activities
    • 3.2.3 Rise in Adoption of Outsourcing Services Expected to Accentuate the Market Growth
  • 3.3 Market Restraints
    • 3.3.1 High Risk Associated with Data Security in Pharmacovigilance Outsourcing
    • 3.3.2 Lack of Availability of Skilled Labor might Hinder the Market Growth
    • 3.3.3 Inadequate Pharmacovigilance System for Herbal Products in Asia Pacific Might Hamper the Market Growth
  • 3.4 Market Opportunities
    • 3.4.1 Huge Scope for Rapid Growth of Pharmacovigilance Market in Emerging Economies
    • 3.4.2 Shift in Preference for Outsourcing among Various Pharmaceutical and Life Sciences Companies
  • 3.5 Porter's Five Forces Analysis: Global Pharmacovigilance Market
    • 3.5.1 Bargaining Power of Suppliers
    • 3.5.2 Bargaining Power of Buyers
    • 3.5.3 Threat of Substitutes
    • 3.5.4 Threat of New Entrants
    • 3.5.5 Competitive Rivalry
  • 3.6 Market Attractiveness Analysis: Global Pharmacovigilance Market, by Geography
  • 3.7 Competitive Landscape
    • 3.7.1 Market Share Analysis: Global Pharmacovigilance Market, 2013 (Value %)

Chapter 4 Global Pharmacovigilance Market, by Phases of Drug Development

  • 4.1 Overview
    • 4.1.1 Global Pharmacovigilance Market Revenue, by Phases of Drug Development, 2012 - 2020 (USD Million)
    • 4.1.2 Comparative Analysis: Global Pharmacovigilance Market Revenue, by Type of Clinical Trial Phases, 2013 & 2020 (Value %)
  • 4.2 Preclinical Studies
    • 4.2.1 Global Preclinical Studies Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
  • 4.3 Phase I
    • 4.3.1 Global Phase I Clinical Trial Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
  • 4.4 Phase II
    • 4.4.1 Global Phase II Clinical Trial Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
  • 4.5 Phase III
    • 4.5.1 Global Phase III Clinical Trial Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
  • 4.6 Phase IV or Post Marketing Surveillance
    • 4.6.1 Global Phase IV Clinical Trial Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)

Chapter 5 Global Pharmacovigilance Market, By Type of Methods

  • 5.1 Overview
    • 5.1.1 Global Pharmacovigilance Market Revenue, by Type of Methods , 2012 - 2020 (USD Million)
  • 5.1.2 Comparative Analysis: Global Pharmacovigilance Market Revenue, by Type of Methods, 2013 & 2020 (Value %)
    • 5.3 Spontaneous Reporting
    • 5.3.1 Global Spontaneous Reporting Market Revenue, 2012 - 2020 (USD Million)
  • 5.4 Intensified ADR Reporting
    • 5.4.1 Global Intensified ADR Reporting Market Revenue, 2012 - 2020 (USD Million)
  • 5.5 Targeted Spontaneous Reporting
    • 5.5.1 Global Targeted Spontaneous Reporting Market Revenue, 2012 - 2020 (USD Million)
  • 5.6 Cohort Event Monitoring
    • 5.6.1 Global Cohort Event Monitoring Market Revenue, 2012 - 2020 (USD Million)
  • 5.7 EHR Mining
    • 5.7.1 Global EHR Mining Market Revenue, 2012 - 2020 (USD Million)

Chapter 6 Global Pharmacovigilance Market, by Type Service Providers

  • 6.1 Overview
    • 6.1.1 Global Pharmacovigilance Market Revenue, by Type of Service Providers , 2012 - 2020 (USD Million)
    • 6.1.2 Comparative Analysis: Global Pharmacovigilance Market, by Type of Service Providers, 2013 & 2020 (Value %)
  • 6.2 In-house Pharmacovigilance
    • 6.2.1 Global In-House Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
  • 6.3 Contract Outsourcing
    • 6.3.1 Global Contract Outsourcing Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)

Chapter 7 Global Pharmacovigilance Market, by Geography

  • 7.1 Overview
    • 7.1.1 Global Pharmacovigilance Market Revenue, by Geography, 2012 - 2020 (USD Million)
  • 7.2 North America
    • 7.2.1 North America Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
  • 7.3 Europe
    • 7.3.1 Europe Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
  • 7.4 Asia Pacific
    • 7.4.1 Asia Pacific Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
  • 7.5 Rest of the World (RoW)
    • 7.5.1 RoW Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)

Chapter 8 Recommendations

Chapter 9 Company Profiles

  • 9.1 Accenture plc
    • 9.1.1 Company Overview
    • 9.1.2 Financial Overview
    • 9.1.3 Product Portfolio
    • 9.1.4 Business Strategies
    • 9.1.5 Recent Developments
  • 9.2 Bristol-Myers Squibb
    • 9.2.1 Company Profile
    • 9.2.2 Financial Overview
    • 9.2.3 Product Portfolio
    • 9.2.4 Business Strategies
  • 9.3 Clinquest Group B.V.
    • 9.3.1 Company Overview
    • 9.3.2 Financial Overview
    • 9.3.3 Product Portfolio
    • 9.3.4 Business Strategies
    • 9.3.5 Recent Developments
  • 9.4 Cognizant Technology Solutions
    • 9.4.1 Company Overview
    • 9.4.2 Financial Overview
    • 9.4.3 Product Portfolio
    • 9.4.4 Business Strategies
    • 9.4.5 Recent Developments
  • 9.5 Covance, Inc.
    • 9.5.1 Company Overview
    • 9.5.2 Financial Overview
    • 9.5.3 Product Portfolio
    • 9.5.4 Business Strategies
    • 9.5.5 Recent Developments
  • 9.6 F. Hoffmann-La Roche Ltd.
    • 9.6.1 Company Overview
    • 9.6.2 Financial Overview
    • 9.6.3 Product Portfolio
    • 9.6.4 Business Strategies
    • 9.6.5 Recent Development
  • 9.7 GlaxoSmithKline plc (GSK)
    • 9.7.1 Company Overview
    • 9.7.2 Financial Overview
    • 9.7.3 Product Portfolio
    • 9.7.4 Business Strategies
    • 9.7.5 Recent Developments
  • 9.8 ICON plc
    • 9.8.1 Company Overview
    • 9.8.2 Financial Overview
    • 9.8.3 Product Portfolio
    • 9.8.4 Business Strategy
    • 9.8.5 Recent Developments
  • 9.9 iGATE Corporation
    • 9.9.1 Company Overview
    • 9.9.2 FINANCIAL Overview
    • 9.9.3 Product Portfolio
    • 9.9.4 Business Strategies
    • 9.9.5 Recent Developments
  • 9.10 iMEDGlobal Corporation
    • 9.10.1 Company Overview
    • 9.10.2 Financial Overview
    • 9.10.3 Product Portfolio
    • 9.10.4 Business Strategies
    • 9.10.5 Recent Developments
  • 9.11 inVentiv Health, Inc.
    • 9.11.1 Company Overview
    • 9.11.2 Financial Overview
    • 9.11.3 Product Portfolio
    • 9.11.4 Business Strategies
    • 9.11.5 Recent Developments
  • 9.12 Novartis International AG
    • 9.12.1 Company Overview
    • 9.12.2 Financial Overview
    • 9.12.3 Product Portfolio
    • 9.12.4 Business Strategies
    • 9.12.5 Recent Developments
  • 9.13 PAREXEL International Corporation
    • 9.13.1 Company Overview
    • 9.13.2 Financial Overview
    • 9.13.3 Product Portfolio
    • 9.13.4 Recent Developments
  • 9.14 Pfizer, Inc.
    • 9.14.1 Company Overview
    • 9.14.2 Financial Overview
    • 9.14.3 Product Portfolio
    • 9.14.4 Business Strategies
    • 9.14.5 Recent Developments
  • 9.15 Pharmaceutical Product Development, LLC. (PPD)
    • 9.15.1 Company Overview
    • 9.15.2 Financial Overview
    • 9.15.3 Product Portfolio
    • 9.15.4 Business Strategies
    • 9.15.5 Recent Developments
  • 9.16 PRA Health Sciences, Inc.
    • 9.16.1 Company Overview
    • 9.16.2 Financial Overview
    • 9.16.3 Product Portfolio
    • 9.16.4 Business Strategies
    • 9.16.5 Recent Developments
  • 9.17 Quintiles Transnational Holdings, Inc.
    • 9.17.1 Company Overview
    • 9.17.2 Financial Overview
    • 9.17.3 Product Portfolio
    • 9.17.4 Business Strategies
    • 9.17.5 Recent Developments
  • 9.18 Sanofi
    • 9.18.1 Company Overview
    • 9.18.2 Financial Overview
    • 9.18.3 Product Portfolio
    • 9.18.4 Business Strategies
    • 9.18.5 Recent Developments
  • 9.19 Synowledge LLC
    • 9.19.1 Company Overview
    • 9.19.2 Financial Overview
    • 9.19.3 Product Portfolio
    • 9.19.4 Business Strategies
    • 9.19.5 Recent Developments
  • 9.20 Wipro Limited
    • 9.20.1 Company Overview
    • 9.20.2 Financial Overview
    • 9.20.3 Product Portfolio
    • 9.20.4 Business Strategies

List of Figures

  • FIG. 1 Drug Safety From Molecule to Market
  • FIG. 2 Pharmacovigilance: Market Segmentation
  • FIG. 3 Global Pharmacovigilance Market, by Phases of Drug Development, 2013 (USD Million)
  • FIG. 4 Global Pharmacovigilance Market, by Type of Service Providers, 2013 (USD Million)
  • FIG. 5 Global Pharmacovigilance Market, by Type of Methods, 2013 (USD Million)
  • FIG. 6 Comparative Analysis: Global Pharmacovigilance Market, by Geography, 2103 (Value %)
  • FIG. 7 Porter's Five Forces Analysis: Global Pharmacovigilance Market
  • FIG. 8 Market Attractiveness Analysis: Global Pharmacovigilance Market, by Geography (2013)
  • FIG. 9 Global Pharmacovigilance Market Share Analysis, by Key Players, 2013 (%)
  • FIG. 10 Safety Services : Product Lifecycle
  • FIG. 11 Comparative Analysis: Global Pharmacovigilance Market Revenue, by Phases of Drug Development, 2013 & 2020 (Value %)
  • FIG. 12 Global Preclinical Studies Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 13 Global Phase I Clinical Trial Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 14 Global Phase II Clinical Trial Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 15 Global Phase III Clinical Trial Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 16 Global Phase IV Clinical Trial Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 17 Comparison of Methods: Pharmacovigilance reporting
  • FIG. 18 Comparative Analysis: Global Pharmacovigilance Market Revenue, by Type of Methods, 2013 & 2020 (Value %)
  • FIG. 19 Global Spontaneous Reporting Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 20 Global Intensified ADR Reporting Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 21 Global Targeted Spontaneous Reporting Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 22 Global Cohort Event Monitoring Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 23 Global EHR Mining Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 24 End-to-End Safety Across the Lifecycle
  • FIG. 25 Comparative Analysis: Global Pharmacovigilance Market, by Type of Service Providers, 2013 & 2020 (Value %)
  • FIG. 26 Global In-House Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 27 Global Contract Outsourcing Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 28 North America Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 29 Europe Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 30 Asia Pacific Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 31 RoW Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 32 Accenture plc.: Annual Revenue 2011- 2013 (USD Billion)
  • FIG. 33 Bristol-Myers Squibb: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 34 Cognizant Technology Solutions: Annual Revenue, 2011- 2013 (USD Million)
  • FIG. 35 COVANCE, Inc.: Annual Revenue, 2011- 2013 (USD Million)
  • FIG. 36 F. Hoffmann-La Roche Ltd., Annual Revenue: 2011 - 2013 (USD Million)
  • FIG. 37 GlaxoSmithKline plc (GSK): Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 38 ICON plc: Annual Revenue, 2011 - 2013 ( USD Million)
  • FIG. 39 iGATE Corporation: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 40 Novartis International AG: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 41 PAREXEL International Corporation: Annual Revenue 2011 - 2013 (USD Million)
  • FIG. 42 Pfizer, Inc.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 43 PRA Health Sciences, Inc., Annual Revenue: 2012 - 2014 (USD Million)
  • FIG. 44 Quintiles Transnational Holdings, Inc.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 45 Sanofi: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 46 Wipro Limited: Annual Revenue 2011 - 2013 (USD Million)

List of Tables

  • TABLE 1 Market Snapshot : Pharmacovigilance Market
  • TABLE 2 Global Pharmacovigilance Market Revenue, by Phases of Drug Development, 2012 - 2020 (USD Million)
  • TABLE 3 Global Pharmacovigilance Market Revenue, by Type of Methods, 2012 - 2020 (USD Million)
  • TABLE 4 Global Pharmacovigilance Market Revenue, by Type of Service Providers, 2012 - 2020 (USD Million)
  • TABLE 5 Global Pharmacovigilance Market Revenue, by Geography, 2012 - 2020 (USD Million)
Back to Top